Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat

Gilead Sciences, Inc. (GILD) reported better-than-expected results in the first quarter, as its loss was narrower than expected and sales beat estimates.GILD’s first-quarter adjusted loss per share of $1.32 per share was narrower than the Zacks Consensus Estimate of a loss of $1.49. In the year-ago quarter, the company reported adjusted earnings of $1.37 per share.The year-over-year decrease was due to an acquired in-process research and development (IPR&D) charge of $3.9 billion, or $3.14 per share, relate ...